270 related articles for article (PubMed ID: 21423795)
1. Rare and frequent promoter methylation, respectively, of TSHZ2 and 3 genes that are both downregulated in expression in breast and prostate cancers.
Yamamoto M; Cid E; Bru S; Yamamoto F
PLoS One; 2011 Mar; 6(3):e17149. PubMed ID: 21423795
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays.
Kron K; Pethe V; Briollais L; Sadikovic B; Ozcelik H; Sunderji A; Venkateswaran V; Pinthus J; Fleshner N; van der Kwast T; Bapat B
PLoS One; 2009; 4(3):e4830. PubMed ID: 19283074
[TBL] [Abstract][Full Text] [Related]
3. Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer.
Schayek H; Bentov I; Jacob-Hirsch J; Yeung C; Khanna C; Helman LJ; Plymate SR; Werner H
Horm Metab Res; 2012 Jun; 44(7):511-9. PubMed ID: 22495974
[TBL] [Abstract][Full Text] [Related]
4. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
[TBL] [Abstract][Full Text] [Related]
5. Global reactivation of epigenetically silenced genes in prostate cancer.
Ibragimova I; Ibáñez de Cáceres I; Hoffman AM; Potapova A; Dulaimi E; Al-Saleem T; Hudes GR; Ochs MF; Cairns P
Cancer Prev Res (Phila); 2010 Sep; 3(9):1084-92. PubMed ID: 20699414
[TBL] [Abstract][Full Text] [Related]
6. HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma.
Yamashita K; Kim MS; Park HL; Tokumaru Y; Osada M; Inoue H; Mori M; Sidransky D
Mol Cancer Res; 2008 Jan; 6(1):31-41. PubMed ID: 18234960
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
8. Stage-specific methylome screen identifies that NEFL is downregulated by promoter hypermethylation in breast cancer.
Kang S; Kim B; Park SB; Jeong G; Kang HS; Liu R; Kim SJ
Int J Oncol; 2013 Nov; 43(5):1659-65. PubMed ID: 24026393
[TBL] [Abstract][Full Text] [Related]
9. Microarray-based analysis of whole-genome DNA methylation profiling in early detection of breast cancer.
Li SY; Wu HC; Mai HF; Zhen JX; Li GS; Chen SJ
J Cell Biochem; 2019 Jan; 120(1):658-670. PubMed ID: 30203578
[TBL] [Abstract][Full Text] [Related]
10. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
11. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
Shames DS; Girard L; Gao B; Sato M; Lewis CM; Shivapurkar N; Jiang A; Perou CM; Kim YH; Pollack JR; Fong KM; Lam CL; Wong M; Shyr Y; Nanda R; Olopade OI; Gerald W; Euhus DM; Shay JW; Gazdar AF; Minna JD
PLoS Med; 2006 Dec; 3(12):e486. PubMed ID: 17194187
[TBL] [Abstract][Full Text] [Related]
12. Homeobox D10 gene, a candidate tumor suppressor, is downregulated through promoter hypermethylation and associated with gastric carcinogenesis.
Wang L; Chen S; Xue M; Zhong J; Wang X; Gan L; Lam EK; Liu X; Zhang J; Zhou T; Yu J; Jin H; Si J
Mol Med; 2012 May; 18(1):389-400. PubMed ID: 22160393
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
14. Survey of differentially methylated promoters in prostate cancer cell lines.
Wang Y; Yu Q; Cho AH; Rondeau G; Welsh J; Adamson E; Mercola D; McClelland M
Neoplasia; 2005 Aug; 7(8):748-60. PubMed ID: 16207477
[TBL] [Abstract][Full Text] [Related]
15. Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells.
Mishra DK; Chen Z; Wu Y; Sarkissyan M; Koeffler HP; Vadgama JV
Mol Cancer Ther; 2010 Jan; 9(1):33-45. PubMed ID: 20053773
[TBL] [Abstract][Full Text] [Related]
16. An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
Holm K; Staaf J; Lauss M; Aine M; Lindgren D; Bendahl PO; Vallon-Christersson J; Barkardottir RB; Höglund M; Borg Å; Jönsson G; Ringnér M
Breast Cancer Res; 2016 Feb; 18(1):27. PubMed ID: 26923702
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells.
Mathews LA; Hurt EM; Zhang X; Farrar WL
Mol Cancer; 2010 Oct; 9():267. PubMed ID: 20929579
[TBL] [Abstract][Full Text] [Related]
18. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.
Roll JD; Rivenbark AG; Jones WD; Coleman WB
Mol Cancer; 2008 Jan; 7():15. PubMed ID: 18221536
[TBL] [Abstract][Full Text] [Related]
19. Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer.
Chang G; Xu S; Dhir R; Chandran U; O'Keefe DS; Greenberg NM; Gingrich JR
Clin Cancer Res; 2010 Nov; 16(22):5390-401. PubMed ID: 21062931
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer.
Liu WB; Han F; Du XH; Jiang X; Li YH; Liu Y; Chen HQ; Ao L; Cui ZH; Cao J; Liu JY
Int J Cancer; 2014 Mar; 134(6):1311-22. PubMed ID: 24037716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
